Akebia Therapeutics (AKBA) Non-Current Assets (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Non-Current Assets of $119.0 million for Q1 2026, up 11.88% year-over-year from $106.4 million in Q1 2025, and down 3.7% quarter-over-quarter from $123.6 million in Q4 2025.
Akebia Therapeutics (AKBA) Non-Current Assets (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Non-Current Assets for 14 consecutive years, with $119.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 11.88% year-over-year to $119.0 million; the TTM figure through Mar 2026 stood at $459.4 million (up 7.25% YoY), while the FY2025 annual figure was $123.6 million, up 15.7% from the prior year.
- Non-Current Assets fell to $119.0 million in Q1 2026 per AKBA's latest filing, from $123.6 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $236.7 million in Q1 2022 and bottomed at $105.8 million in Q3 2025.
- Historically, Non-Current Assets has averaged $139.8 million across 5 years, with a median of $123.6 million in 2023.
- Annual changes were most pronounced in 2023 — Non-Current Assets slumped 38.97% — and 2025, when it increased 15.7%.
- Akebia Therapeutics' Non-Current Assets stood at $170.9 million in 2022, then declined by 27.69% to $123.6 million in 2023, then dropped by 13.53% to $106.8 million in 2024, then grew by 15.7% to $123.6 million in 2025, then slipped by 3.7% to $119.0 million in 2026.
- Business Quant data shows AKBA's Non-Current Assets at $119.0 million in Q1 2026, $123.6 million in Q4 2025, and $105.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | 120.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 120.11 Mn |
| Mar 31, 2026 | 119.04 Mn |
| Dec 31, 2025 | 123.61 Mn |
| Sep 30, 2025 | 105.82 Mn |
| Jun 30, 2025 | 110.94 Mn |
| Mar 31, 2025 | 106.40 Mn |
| Dec 31, 2024 | 106.84 Mn |
| Sep 30, 2024 | 107.02 Mn |
| Jun 30, 2024 | 108.10 Mn |
| Mar 31, 2024 | 112.53 Mn |
| Dec 31, 2023 | 123.55 Mn |
| Sep 30, 2023 | 125.40 Mn |
| Jun 30, 2023 | 135.27 Mn |
| Mar 31, 2023 | 160.13 Mn |
| Dec 31, 2022 | 170.87 Mn |
| Sep 30, 2022 | 202.04 Mn |
| Jun 30, 2022 | 221.63 Mn |
| Mar 31, 2022 | 236.66 Mn |
| Dec 31, 2021 | 258.20 Mn |
| Sep 30, 2021 | 272.18 Mn |